GLSI

GLSI

USD

Greenwich LifeSciences Inc. Common Stock

$9.630-0.015 (-0.156%)

Real-time Price

Healthcare
Biotechnology
United States

Price Chart

Loading Chart...

Key Metrics

Market Metrics
Company Fundamentals
Trading Stats

Market Metrics

Open

$9.645

High

$9.915

Low

$9.600

Volume

0.02M

Company Fundamentals

Market Cap

128.7M

Industry

Biotechnology

Country

United States

Trading Stats

Avg Volume

0.08M

Exchange

NCM

Currency

USD

52-Week Range

Low $8.06Current $9.630High $18.75

Related News

GlobeNewswire

Greenwich LifeSciences Provides Global Update on FLAMINGO-01

STAFFORD, Texas, April 03, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,

View more
Greenwich LifeSciences Provides Global Update on FLAMINGO-01
GlobeNewswire

Greenwich LifeSciences Announces Positive Immune Response Data from FLAMINGO-01 Phase III Clinical Trial

STAFFORD, Texas, April 02, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,

View more
Greenwich LifeSciences Announces Positive Immune Response Data from FLAMINGO-01 Phase III Clinical Trial
GlobeNewswire

Greenwich LifeSciences Extends Lock-up of Directors and Officers to March 31, 2026

STAFFORD, Texas, March 27, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,

View more
Greenwich LifeSciences Extends Lock-up of Directors and Officers to March 31, 2026
GlobeNewswire

Greenwich LifeSciences Provides Update on Open Label Safety Data from FLAMINGO-01

STAFFORD, Texas, March 17, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,

View more
Greenwich LifeSciences Provides Update on Open Label Safety Data from FLAMINGO-01